Biblio

Author Title [ Type

] Year

Filters: Author is Nieto, Yago [Clear All Filters]

Journal Article

Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leuk Res. 2016;47:100-108.

Nieto Y, Yang Z, Valdez BC, Kundu S, Bashir Q, Ramdial J, Srour S, Qazilbash M. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts. Am J Hematol. 2023.

Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 B cell tumors: a phase 1/2 trial. Nat Med. 2024.

Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, et al. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023.

Pinnix CC, Dabaja B, Ahmed MAmin, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, et al. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by (18)Fluorodeoxyglucose Positron Emission Tomography. Int J Radiat Oncol Biol Phys. 2015;92(1):113-121.

Brammer JE, Khouri I, Marin D, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Champlin RE, Hosing C, Kebriaei P. Stem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma. 2016:1-6.

Valdez BC, Yuan B, Murray D, Ramdial JLeon, Nieto Y, Popat U, Tang X, Andersson BS. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells. Front Oncol. 2023;13:1287444.

Valdez BC, Tsimberidou AM, Yuan B, Nieto Y, Baysal MA, Chakraborty A, Andersen CR, Andersson BS. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy. Oncotarget. 2024;15:361-373.

Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, et al. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021:JCO2002608.

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Kerbauy LNassif, Overman B, Thall P, Kaplan M, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545-553.

Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, et al. Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes. Transplant Cell Ther. 2022.

Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, et al. Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015.

Pages